ClinicalTrials.gov
public full text
Public Domain
Safety and Activity of Digoxin With Decitabine in Adult AML and MDS
The primary hypothesis is that digoxin can be safely added to decitabine and will increase the response rates in medically unfit patients with newly diagnosed AML/MDS or those with relapsed/refractory AML/MDS. Furthermore, it is hypothesized that the addition of digoxin to decitabine will result in distinct epigenetic alterations in AML/MDS patients.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS#993532
- Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)#1088817
- Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome#865414
- Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q#1057460
- Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia#884716
Record · ID 846861
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive